BC Innovations | Feb 11, 2019
Distillery Therapeutics


INDICATION: Mesothelioma Cell and mouse studies suggest GHRH receptor antagonists could help treat malignant pleural mesothelioma (MPM). In two human-derived MPM cell lines and patient-derived MPM cells, two previously identified GHRH receptor antagonists inhibited growth...
BC Innovations | Jan 25, 2017
Distillery Therapeutics


INDICATION: Retinoblastoma In vitro studies suggest antagonizing the GHRH receptor could help treat retinoblastoma. In a human retinoblastoma cell line, GHRH receptor expression was higher than in normal eye-derived cell lines. In the retinoblastoma cell...
BC Innovations | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Dyslipidemia Rat studies suggest GHRH receptor antagonists could help treat dyslipidemia associated with Type I diabetes. A rat model of Type I diabetes had higher GHRH receptor levels in the small intestine...
BioCentury | Sep 8, 2014
Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne Pharmaceuticals Inc. is developing peptide antagonists that target three different cancer growth pathways and could provide an alternative for prostate cancer patients who have become insensitive to hormone-based therapies. The company plans to enter...
Items per page:
1 - 4 of 4